journal
MENU ▼
Read by QxMD icon Read
search

Pharmaceutical Patent Analyst

journal
https://www.readbyqxmd.com/read/28534435/genome-editing-technologies-and-patent-landscape-overview
#1
Fairouz Benahmed-Miniuk, Mat Kresz, Jitendra K Kanaujiya, Christopher D Southgate
Unlike with zinc finger nuclease and transcriptional activator-like effector nuclease DNA modification technologies that rely on lead proteins, developed through expensive and time-consuming processes, the clustered regularly interspaced short palindromic repeat (CRISPR)/Cas system has rapidly emerged as the most promising gene-editing technology to date for the modification of any selected DNA sequence. CRISPR is receiving tremendous fanfare due, in part, to its potential to provide a means to fundamentally alter medical genetics and especially cancer medicine...
May 23, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28485681/humira-recent-developments
#2
Peter Norman
No abstract text is available yet for this article.
May 9, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28485677/january-2017-extended-scope-of-patent-term-extension-japan-is-progenerics-debiopharm-international-sa-vs-towa-pharmaceutical-co-ltd
#3
Takeshi S Komatani
No abstract text is available yet for this article.
May 9, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28485666/are-therapeutic-antibodies-still-patentable-at-the-european-patent-office
#4
Vicki Allen, Graham Matthew Lewis
No abstract text is available yet for this article.
May 9, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28485665/patent-highlights-december-2016-january-2017
#5
Hermann Am Mucke
No abstract text is available yet for this article.
May 9, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28485650/intellectual-property-and-biodiversity-interplay
#6
Ravi Bhola, Shreya Dave
Potentially divergent objectives and thereby obligations under the Convention on Biodiversity and Trade-Related Aspects of Intellectual Property Rights Agreement are also reflected in respective domestic legislations in India. The review article focuses on Biological Diversity Act, 2002 vis-à-vis Patents Act, 1970 of India with intricacies involved thereunder. Authors have analyzed the obligations under these domestic legislations. The article goes on to make a few suggestions to aid effective implementation of both the statutes...
May 9, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28343406/corrigendum
#7
(no author information available yet)
No abstract text is available yet for this article.
March 27, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28274178/the-consequences-of-double-examination-for-pharmaceutical-patent-applications-in-brazil
#8
Gabriela Salerno
No abstract text is available yet for this article.
March 9, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28248129/key-points-of-the-new-spanish-patent-act
#9
Teresa Mercadal Menchaca
No abstract text is available yet for this article.
March 1, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28248151/p2x7-antagonists-for-cns-indications-recent-patent-disclosures
#10
REVIEW
Paolo Pevarello, Silvia Bovolenta, Paola Tarroni, Lorena Za, Elda Severi, Domenica Torino, Rocco Vitalone
P2X7, a ligand-gated purinergic ion channel, has been at the center of intense efforts in the pharmaceutical industry in the last 15 years due to the growing appreciation of its role in inflammation. Since 2008-2009, increased focus on CNS available compounds has led to the publication of various patents on behalf of several pharmaceutical companies. This patent review aims at analyzing the recent patent literature (2008-2016) with a particular emphasis on those patents that are thought to deal with CNS penetrant compounds on the basis of their physicochemical features, the assays described in the patents and the uses these compounds are claimed for...
March 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28248128/patent-highlights-october-november-2016
#11
Hermann Am Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
March 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28248125/drug-delivery-via-porous-silicon-a-focused-patent-review
#12
REVIEW
Paulina A Kulyavtsev, Roxanne P Spencer
Although silicon is more commonly associated with computer chips than with drug delivery, with the discovery that porous silicon is a viable biocompatible material, mesoporous silicon with pores between 2 and 50 nm has been loaded with small molecule and biomolecule therapeutics and safely implanted for controlled release. As porous silicon is readily oxidized, porous silica must also be considered for drug delivery applications. Since 2010, only a limited number of US patents have been granted, primarily for ophthalmologic and immunotherapy applications, in contrast to the growing body of technical literature in this area...
March 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28201948/enbrel-and-etanercept-biosimilars-a-tale-of-two-patent-systems
#13
Peter Norman
No abstract text is available yet for this article.
February 16, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28198642/upcoming-challenges-in-intellectural-property-presented-by-emerging-pharmaceutical-technologies
#14
Takeshi S Komatani
No abstract text is available yet for this article.
February 15, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28181455/how-cuozzo-will-impact-the-interplay-between-post-grant-proceedings-and-hatch-waxman-litigation
#15
Natasha Mishra, Patrick A Doody, Raj S Davé
No abstract text is available yet for this article.
February 9, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28155570/pharmaceutical-patent-protection-the-united-states-and-japan-in-comparative-perspective
#16
Shinya Kimura, Carlyn A Burton
No abstract text is available yet for this article.
February 3, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28155581/patent-highlights-august-september-2016
#17
Hermann Am Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
January 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28155578/novel-linkers-and-connections-for-antibody-drug-conjugates-to-treat-cancer-and-infectious-disease
#18
Thomas H Pillow
Antibody-drug conjugates (ADCs) are an exciting therapeutic, combining the extreme potency of a small molecule cytotoxic drug with the exquisite selectivity of a monoclonal antibody. Despite the promising concept and many decades of research and clinical experiments, only two ADCs are approved for human use. Among the lessons learned, have been the need for highly stable and potentially releasable linkers and the empirical nature of therapeutic index supporting the testing of many diverse cytotoxics, many requiring new linker connections for the drug's available functional groups...
January 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/27848274/is-inherent-disclosure-sufficient-for-priority-claim-monoclonal-versus-chimeric-humanized-antibody-estoppels
#19
Takeshi S Komatani
No abstract text is available yet for this article.
September 2016: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/27813447/fostering-innovative-product-development-for-neglected-tropical-diseases-through-partnerships
#20
Amy Starr, Katy M Graef, Jennifer Dent
Neglected tropical diseases are a group of infectious diseases that threaten and impact a significant portion of individuals living in low- and middle-income countries. Healthcare product R&D, which has been relatively limited for this group of infectious diseases, is timely and requires significant risk and resource investment by companies. Regardless of these costs, the global community has recognized the impact on human health that developing products for these diseases could have. Incentives, including 'push' and 'pull' funding, and platforms that support sharing of intellectual property through partnerships, such as The World Intellectual Property Organization Re:Search, are driving R&D...
September 2016: Pharmaceutical Patent Analyst
journal
journal
47821
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"